Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00616018 · ClinicalTrials.gov registry record · Phase 4
Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days
A Phase 4 study of Drug Induced Liver Injury, sponsored by Kennon Heard.
- Completed
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00616018 is a Phase 4 study of Drug Induced Liver Injury that has completed, run by Kennon Heard. The registered enrollment target is 35 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00616018, a Phase 4 study of Drug Induced Liver Injury, has completed, sponsored by Kennon Heard.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
Acetaminophen is commonly used to treat fever or pain. Your body clears acetaminophen by processing it in the liver. During the processing, some of the acetaminophen may bind to proteins in the liver. The protein-acetaminophen product is called an "adduct." After a large acetaminophen overdose, the liver has to process a lot of acetaminophen, so large amounts of adducts are formed. However, we have found that lower levels may be formed even when people take recommended doses. The purpose of this study is to measure the amount of adducts formed when healthy people who do not drink alcohol take normal doses of acetaminophen for 10 days.
Conditions Studied
Interventions
- DRUG acetaminophen
Study Locations (1)
Colorado
- Denver Health Rocky Mountain Poison and Drug Center - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00616018
The ClinicalTrials.gov registry entry for NCT00616018 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kennon Heard, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Drug Induced Liver Injury appearing as the primary indexed condition, and to 1 intervention - of which acetaminophen is the first listed.
NCT00616018 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT00616018 about?
NCT00616018 is a clinical study titled "Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days". Acetaminophen is commonly used to treat fever or pain. Your body clears acetaminophen by processing it in the liver. During the processing, some of the acetaminophen may bind to proteins in the liver. The protein-acetaminophen product is called an "adduct." After a large acetaminophen overdose, the ...
What is the current status of trial NCT00616018?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2007-08. Estimated completion is 2008-01.
What conditions does trial NCT00616018 study?
This clinical trial studies the following conditions: Drug Induced Liver Injury.
What interventions are being tested in trial NCT00616018?
The interventions under investigation include: acetaminophen (DRUG).
Who is sponsoring clinical trial NCT00616018?
This trial is sponsored by Kennon Heard, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00616018 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Induced Liver Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.